Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 5/20 | 0.35 |
| ▸ | GABRA5 | P31644 | 5/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 4/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 4/20 | 0.35 |
| ▸ | GABRA3 | P34903 | 4/20 | 0.35 |
| ▸ | GABRA2 | P47869 | 4/20 | 0.35 |
| ▸ | GABRA4 | P48169 | 3/20 | 0.35 |
| ▸ | GABRA6 | Q16445 | 3/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.32 |
| ▸ | KDM5A | P29375 | 1/20 | 0.31 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.31 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7551034 | 0.81 | GABRA1 (0.36) | GABRA1GABRA5GABRG2GABRB3GABRA3 | |
| SCHEMBL7097977 | 0.76 | GABRA1 (0.34) | GABRA1GABRA5GABRG2GABRB3GABRA3 | |
| SCHEMBL4312425 | 0.73 | MAPT (0.40) | GABRA1GABRA5GABRG2GABRB3GABRA3 | |
| SCHEMBL24838771 | 0.72 | GABRA1 (0.42) | GABRA1GABRA5GABRG2GABRB3GABRA3 | |
| SCHEMBL7716869 | 0.72 | GABRA1 (0.34) | GABRA1GABRA5GABRG2GABRB3GABRA3 | |
| SCHEMBL6948487 | 0.70 | CYP3A4 (0.43) | GABRA1GABRA5GABRG2GABRB3GABRA3 | |
| SCHEMBL5736149 | 0.70 | PYCR1 (0.42) | KDM5AKDM4CKDM5B | |
| SCHEMBL10241971 | 0.70 | TP53 (0.43) | GABRA1GABRA5GABRG2GABRB3GABRA3 | |
| SCHEMBL5737255 | 0.70 | CYP11B1 (0.54) | — | |
| SCHEMBL27215732 | 0.69 | NPC1 (0.37) | GABRA1GABRA5GABRG2GABRB3GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1366036-B1 | COMPOUNDS HAVING ACTIVITY AS INHIBITORS OF CYTOCHROME P450RAI | ALLERGAN INC (US) | 2006-01-11 | — | — | EP | disclosed |
| US-6855512-B2 | Methods for identifying inhibitors of cytochrome P450RAI | ALLERGAN, INC. (US) | 2005-02-15 | — | — | US | disclosed |
| US-6713647-B2 | Compounds having activity as inhibitors of cytochrome P450RAI | ALLERGAN, INC. | 2004-03-30 | — | — | US | disclosed |
| EP-1366036-A2 | COMPOUNDS HAVING ACTIVITY AS INHIBITORS OF CYTOCHROME P450RAI | Allergan, Inc. (US) | 2003-12-03 | — | — | EP | disclosed |
| US-20030186947-A1 | Compounds having activity as inhibitors of cytochrome P450RAI | ALLERGAN, INC. | 2003-10-02 | — | — | US | disclosed |
| US-6603019-B2 | Phenylacetic or heteroarylacetic acid derivatives, retinoic acid inducible enzyme, used to treat diseases responsive to retinoids | ALLERGAN, INC. | 2003-08-05 | — | — | US | disclosed |
| EP-1322631-A2 | METHODS OF PROVIDING AND USING COMPOUNDS ( RETINOIDS ) HAVING ACTIVITY AS INHIBITORS OF CYTOCHROME P450RAI | Allergan, Inc. (US) | 2003-07-02 | — | — | EP | disclosed |
| US-20030078270-A1 | Methods of providing and using compounds having activity as inhibitors of cytochrome P450RAI | ALLERGAN, INC. | 2003-04-24 | — | — | US | disclosed |
| US-6531599-B2 | RAI=retinoic acid inducible; for example, 4-((8-cyclopropyl-3,4-dihydro-4,4-dimethylspiro(2H-1-benzopyran-2,1' -cyclopropane)-6-yl) ethynyl)-2-fluoro-benzoic acid; use treating diseases responsive to retinoids | ALLERGAN SALES, INC. | 2003-03-11 | — | — | US | disclosed |
| US-20020193578-A1 | Compounds having activity as inhibitors of cytochrome P450RAI | ALLERGAN, INC. | 2002-12-19 | — | — | US | disclosed |
| US-6380256-B1 | FOR THERAPY OF DISEASES RESPONSIVE TO TREATMENT BY RETINOIDS | ALLERGAN SALES, INC. | 2002-04-30 | — | — | US | disclosed |
| US-6369261-B1 | CYCLOPROPYLBENZENE DERIVATIVE OF ACIDS OR ESTERS | ALLERGAN SALES, INC. | 2002-04-09 | — | — | US | disclosed |
| US-6369225-B1 | ENZYME INHIBITORS | ALLERGAN SALES, INC. | 2002-04-09 | — | — | US | disclosed |
| WO-2002026727-A2 | METHODS OF PROVIDING AND USING COMPOUNDS (RETINOIDS) HAVING ACTIVITY AS INHIBITORS OF CYTOCHROME P450RAI | ALLERGAN, INC. (US) | 2002-04-04 | — | — | WO | disclosed |
| US-6359135-B1 | Compounds having activity as inhibitors of cytochrome P450RAI | ALLERGAN SALES, INC. | 2002-03-19 | — | — | US | disclosed |
| WO-2002018361-A2 | COMPOUNDS HAVING ACTIVITY AS INHIBITORS OF CYTOCHROME P450RAI | ALLERGAN, INC. (US) | 2002-03-07 | — | — | WO | disclosed |
| US-6313107-B1 | ADMINISTERING TO MAMMAL TO TREAT DISEASES RESPONSIVE TO TREATMENT BY RETINOIDS | ALLERGAN SALES, INC. | 2001-11-06 | — | — | US | disclosed |
| US-6303785-B1 | SUBSTITUTED N-CYCLOPROPYLTETRAHYDROISOQUINOLINES | ALLERGAN SALES, INC. | 2001-10-16 | — | — | US | disclosed |
| US-6291677-B1 | FOR TREATING SKIN-RELATED DISEASES, INCLUDING, ACTINIC KERATOSES, ARSENIC KERATOSES, INFLAMMATORY AND NON-INFLAMMATORY ACNE, PSORIASIS, ICHTHYOSES AND KERATINIZATION AND HYPERPROLIFERATIVE DISORDERS OF SKIN | ALLERGAN SALES, INC. | 2001-09-18 | — | — | US | disclosed |
| US-6252090-B1 | Compounds having activity as inhibitors of cytochrome P450RAI | ALLERGAN SALES, INC. | 2001-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078270-A1 | Methods of providing and using compounds having activity as inhibitors of cytochrome P450RAI | CYP26B1, CYP21A2, ALDH1A2 | GABRA1 709/4885GABRA5 1160/4885GABRG2 1329/4885 |
| US-20030186947-A1 | Compounds having activity as inhibitors of cytochrome P450RAI | RARA, RARB, RARG | GABRA1 618/4885GABRA5 1053/4885GABRG2 1045/4885 |
| US-20020193578-A1 | Compounds having activity as inhibitors of cytochrome P450RAI | RARA, RARB, RARG | GABRA1 478/4885GABRA5 1096/4885GABRG2 1154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.